Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Kister I, Patskovsky Y, Curtin R, Pei J, Perdomo K, Rimler Z, Voloshyna I, Samanovic MI, Cornelius AR, Velmurugu Y, Nyovanie S, Kim JJ, Tardio E, Bacon TE, Zhovtis Ryerson L, Raut P, Pedotti R, Hawker K, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Krogsgaard M, Silverman GJ.
Kister I, et al. Among authors: winger rc.
Ann Neurol. 2022 Jun;91(6):782-795. doi: 10.1002/ana.26346. Epub 2022 Apr 1.
Ann Neurol. 2022.
PMID: 35289960
Free PMC article.